227 related articles for article (PubMed ID: 34991643)
1. Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.
Yates AG; Weglinski CM; Ying Y; Dunstan IK; Strekalova T; Anthony DC
J Neuroinflammation; 2022 Jan; 19(1):8. PubMed ID: 34991643
[TBL] [Abstract][Full Text] [Related]
2. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
3. The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice.
Yamaya M; Shimotai Y; Ohkawara A; Bazarragchaa E; Okamatsu M; Sakoda Y; Kida H; Nishimura H
J Med Virol; 2021 Jun; 93(6):3484-3495. PubMed ID: 33247612
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
[TBL] [Abstract][Full Text] [Related]
5. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
7. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2.
Ianevski A; Yao R; Lysvand H; Grødeland G; Legrand N; Oksenych V; Zusinaite E; Tenson T; Bjørås M; Kainov DE
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578348
[TBL] [Abstract][Full Text] [Related]
9. Persistent Toll-like receptor 7 stimulation induces behavioral and molecular innate immune tolerance.
Michaelis KA; Norgard MA; Levasseur PR; Olson B; Burfeind KG; Buenafe AC; Zhu X; Jeng S; McWeeney SK; Marks DL
Brain Behav Immun; 2019 Nov; 82():338-353. PubMed ID: 31499172
[TBL] [Abstract][Full Text] [Related]
10. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.
Sendo T; Itoh Y; Goromaru T; Sumimura T; Saito M; Aki K; Yano T; Oishi R
Br J Pharmacol; 2003 Mar; 138(5):959-67. PubMed ID: 12642398
[TBL] [Abstract][Full Text] [Related]
11. TLR7 Agonist Suppresses Group 2 Innate Lymphoid Cell-mediated Inflammation via IL-27-Producing Interstitial Macrophages.
Okuzumi S; Miyata J; Kabata H; Mochimaru T; Kagawa S; Masaki K; Irie M; Morita H; Fukunaga K
Am J Respir Cell Mol Biol; 2021 Sep; 65(3):309-318. PubMed ID: 34003734
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis.
Oh HS; Kim T; Gu DH; Lee TS; Kim TH; Shin S; Shin BS
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335247
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics.
Quinn TM; Gaughan EE; Bruce A; Antonelli J; O'Connor R; Li F; McNamara S; Koch O; MacKintosh C; Dockrell D; Walsh T; Blyth KG; Church C; Schwarze J; Boz C; Valanciute A; Burgess M; Emanuel P; Mills B; Rinaldi G; Hardisty G; Mills R; Findlay EG; Jabbal S; Duncan A; Plant S; Marshall ADL; Young I; Russell K; Scholefield E; Nimmo AF; Nazarov IB; Churchill GC; McCullagh JSO; Ebrahimi KH; Ferrett C; Templeton K; Rannard S; Owen A; Moore A; Finlayson K; Shankar-Hari M; Norrie J; Parker RA; Akram AR; Anthony DC; Dear JW; Hirani N; Dhaliwal K
EBioMedicine; 2022 Feb; 76():103856. PubMed ID: 35152152
[TBL] [Abstract][Full Text] [Related]
14. Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood-spinal cord barrier breakdown during acute spinal cord injury in rats.
Zhao C; Zhou T; Zhao X; Pang Y; Li W; Fan B; Li M; Liu X; Ma L; Zhang J; Sun C; Shen W; Kong X; Yao X; Feng S
J Neuroinflammation; 2022 Jul; 19(1):189. PubMed ID: 35842640
[TBL] [Abstract][Full Text] [Related]
15. Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice.
Matsubara H; Imai T; Tsuji S; Oka N; Egashira Y; Enomoto Y; Nakayama N; Nakamura S; Shimazawa M; Iwama T; Hara H
J Pharmacol Sci; 2022 Jan; 148(1):65-72. PubMed ID: 34924132
[TBL] [Abstract][Full Text] [Related]
16. Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment.
Huang X; Pearce R; Omenn GS; Zhang Y
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209110
[TBL] [Abstract][Full Text] [Related]
17. Immune response in the duck intestine following infection with low-pathogenic avian influenza viruses or stimulation with a Toll-like receptor 7 agonist administered orally.
Volmer C; Soubies SM; Grenier B; Guérin JL; Volmer R
J Gen Virol; 2011 Mar; 92(Pt 3):534-43. PubMed ID: 21123544
[TBL] [Abstract][Full Text] [Related]
18. Nafamostat mesilate inhibits linezolid metabolism via its antioxidant effects.
Kuriyama N; Matsumoto K; Morita K; Shimomura Y; Hara Y; Hasegawa D; Nakamura T; Yamashita C; Kato Y; Komura H; Nishida O
Ther Apher Dial; 2020 Oct; 24(5):499-502. PubMed ID: 32524735
[TBL] [Abstract][Full Text] [Related]
19. Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition.
Schwertz H; Carter JM; Russ M; Schubert S; Schlitt A; Buerke U; Schmidt M; Hillen H; Werdan K; Buerke M
J Cardiovasc Pharmacol; 2008 Aug; 52(2):151-60. PubMed ID: 18670364
[TBL] [Abstract][Full Text] [Related]
20. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.
M P; Reddy GJ; Hema K; Dodoala S; Koganti B
Eur J Pharmacol; 2021 Jan; 890():173688. PubMed ID: 33130280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
